旗舰公司开创了Serif生物医药,开发改造的DNA疗法. Flagship Pioneering launches Serif Biomedicines to develop modified DNA therapies.

旗舰先公司推出了Serif Biomedicines,开发"改造DNA"疗法,结合mRNA和基因治疗的好处. Flagship Pioneering launched Serif Biomedicines to develop "modified DNA" therapies, combining the benefits of mRNA and gene treatments. 该平台使用合成DNA和mRNA为人体提供内部制造药物的指令,旨在通过重复剂量和更低成本治疗罕见疾病和免疫障碍. This platform uses synthetic DNA and mRNA to deliver instructions for the body to produce drugs internally, aiming to treat rare diseases and immune disorders with repeat dosing and lower costs. 凭借5千万美元的支持,Serif是Flagship在2026年推出的第一家新公司. Backed by $50 million, Serif is the first new company launched by Flagship in 2026.